Muthiah Vaduganathan MD, MPHAttending Cardiologist, Division of Cardiovascular Medicine, Brigham and Women’s Hospital; Instructor of Medicine, Harvard Medical School, Boston, Massachusetts
Dr. Vaduganathan is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA). His research focuses on drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 300 peer-reviewed publications. Dr. Vaduganathan serves on the editorial boards of the European Journal of Heart Failure, JACC Heart Failure (Social Media / CME Editor), & JACC (FIT / Early Career Section Editor). He serves as a co-chair on an FDA Think Tank committee on improving future clinical trials in HF. He participates as an investigator and Clinical Endpoints Committee member for ongoing advanced-phase trials in HF / post-MI LV dysfunction.
Dr Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Relypsa, and Roche Diagnostics, speaker engagements with Novartis and Roche Diagnostics, and participates on clinical endpoint committees for studies sponsored by Galmed and Novartis.
Recent Contributions to PracticeUpdate:
- Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum
- Effects of Combined RAAS-Inhibitor and Beta-Blocker Treatment on Outcomes in HFrEF
- Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With CAD